ArticleAnnals of hematology2025

Treatment outcomes of BTK inhibitors and venetoclax with or without anti-CD20 monoclonal antibody in relapsed or refractory mantle cell lymphoma.

Ping Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.